# Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults

> **NCT06726863** · PHASE1 · COMPLETED · sponsor: **CSL Behring** · enrollment: 22 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Vamifeport IRF
- **DRUG:** Vamifeport PR1
- **DRUG:** Vamifeport PR2

## Key facts

- **NCT ID:** NCT06726863
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-22
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-02-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726863, "Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06726863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*